{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:39:04Z","timestamp":1789331944730,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303188"],"award-info":[{"award-number":["82303188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400870"],"award-info":[{"award-number":["82400870"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68156-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:16:25Z","timestamp":1768216585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Yonglong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-817X","authenticated-orcid":false,"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-3634","authenticated-orcid":false,"given":"Huifang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4854","authenticated-orcid":false,"given":"Zifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-6034","authenticated-orcid":false,"given":"Limin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0284-8377","authenticated-orcid":false,"given":"Jianfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8546-7472","authenticated-orcid":false,"given":"Bixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-0970","authenticated-orcid":false,"given":"Ze-yang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"68156_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"68156_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"68156_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa, L., Finn, R. S. & Sangro, B. Combination immunotherapy for hepatocellular carcinoma. J. Hepatol. 79, 506\u2013515 (2023).","journal-title":"J. Hepatol."},{"key":"68156_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835\u20131847 (2023).","journal-title":"Lancet"},{"key":"68156_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1399\u20131410 (2023).","journal-title":"Lancet Oncol."},{"key":"68156_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi, K. & Ruffell, B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer 9, 381\u2013396 (2023).","journal-title":"Trends Cancer"},{"key":"68156_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia, D. et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153, 812\u2013826 (2017).","journal-title":"Gastroenterology"},{"key":"68156_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","volume":"72","author":"C Montironi","year":"2023","unstructured":"Montironi, C. et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 72, 129\u2013140 (2023).","journal-title":"Gut"},{"key":"68156_CR9","doi-asserted-by":"crossref","unstructured":"You, W. et al. Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma. Gut 74, 679\u2013681 (2024).","DOI":"10.1136\/gutjnl-2024-333375"},{"key":"68156_CR10","doi-asserted-by":"crossref","unstructured":"Li, B., Cao, Y., Li, Y., Cheng, C. & Yu, D. Letter to the editor: the inflamed subclass predicts immunotherapy response\u2014external validations. Gut gutjnl, 2022\u2013328130 (2022).","DOI":"10.1136\/gutjnl-2022-328130"},{"key":"68156_CR11","doi-asserted-by":"publisher","first-page":"997316","DOI":"10.3389\/fimmu.2022.997316","volume":"13","author":"G Cai","year":"2022","unstructured":"Cai, G. et al. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses. Front. Immunol. 13, 997316 (2022).","journal-title":"Front. Immunol."},{"key":"68156_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/gutjnl-2023-331342","volume":"73","author":"N Cai","year":"2024","unstructured":"Cai, N. et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut 73, 985\u2013999 (2024).","journal-title":"Gut"},{"key":"68156_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/gutjnl-2023-331647","volume":"73","author":"M Barcena-Varela","year":"2024","unstructured":"Barcena-Varela, M. & Berraondo, P. Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma. Gut 73, 890\u2013891 (2024).","journal-title":"Gut"},{"key":"68156_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie, M. et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J. Hepatol. 79, 109\u2013125 (2023).","journal-title":"J. Hepatol."},{"key":"68156_CR15","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi, C. et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 74, 2544\u20132560 (2021).","journal-title":"Hepatology"},{"key":"68156_CR16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li, H. et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology 156, 1849\u20131861.e13 (2019).","journal-title":"Gastroenterology"},{"key":"68156_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcmgh.2022.09.015","volume":"15","author":"T Wong","year":"2023","unstructured":"Wong, T. et al. Protein tyrosine kinase 7 (PTK7) promotes metastasis in hepatocellular carcinoma via SOX9 regulation and TGF-\u03b2 signaling. Cell. Mol. Gastroenterol. Hepatol. 15, 13\u201337 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"68156_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161929","volume":"133","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression. J. Clin. Investig. 133, e161929 (2023).","journal-title":"J. Clin. Investig."},{"key":"68156_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add3231","volume":"9","author":"M Chaib","year":"2023","unstructured":"Chaib, M. et al. Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer. Sci. Adv. 9, eadd3231 (2023).","journal-title":"Sci. Adv."},{"key":"68156_CR20","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-21-3899","volume":"82","author":"JC Wang","year":"2022","unstructured":"Wang, J. C. et al. PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma. Cancer Res. 82, 3307\u20133320 (2022).","journal-title":"Cancer Res."},{"key":"68156_CR21","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912\u20131934 (2002).","journal-title":"Science"},{"key":"68156_CR22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"68156_CR23","unstructured":"Cancer, G. A. R. N. E. a. w. e. & Network, C. G. A. R. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341.e23 (2017)."},{"key":"68156_CR24","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385\u20137392 (2009).","journal-title":"Cancer Res."},{"key":"68156_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"68156_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro, J., Ziol, M., Paradis, V. & Zucman-Rossi, J. Molecular and histological correlations in liver cancer. J. Hepatol. 71, 616\u2013630 (2019).","journal-title":"J. Hepatol."},{"key":"68156_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13851-6","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Modulation of brain cation-Cl(-) cotransport via the SPAK kinase inhibitor ZT-1a. Nat. Commun. 11, 78 (2020).","journal-title":"Nat. Commun."},{"key":"68156_CR28","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41556-022-00989-7","volume":"24","author":"BT Wesley","year":"2022","unstructured":"Wesley, B. T. et al. Single-cell atlas of human liver development reveals pathways directing hepatic cell fates. Nat. Cell Biol. 24, 1487\u20131498 (2022).","journal-title":"Nat. Cell Biol."},{"key":"68156_CR29","doi-asserted-by":"crossref","unstructured":"Kang, M. et al. Improved reconstruction of single-cell developmental potential with CytoTRACE 2. Nat. Methods 22, 2258\u20132263 (2025).","DOI":"10.1038\/s41592-025-02857-2"},{"key":"68156_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science 367, 405\u2013411 (2020).","journal-title":"Science"},{"key":"68156_CR31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"68156_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to the exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"68156_CR33","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-17-3509","volume":"24","author":"D Tamborero","year":"2018","unstructured":"Tamborero, D. et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin. Cancer Res. 24, 3717\u20133728 (2018).","journal-title":"Clin. Cancer Res."},{"key":"68156_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2005.06.005","volume":"8","author":"W Wei","year":"2005","unstructured":"Wei, W., Jin, J., Schlisio, S., Harper, J. W. & Kaelin, W. G. Jr The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25\u201333 (2005).","journal-title":"Cancer Cell"},{"key":"68156_CR35","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1136\/gutjnl-2018-317440","volume":"68","author":"DM Xiang","year":"2019","unstructured":"Xiang, D. M. et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut 68, 1858\u20131871 (2019).","journal-title":"Gut"},{"key":"68156_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","volume":"42","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell 42, 535\u2013551.e8 (2024).","journal-title":"Cancer Cell"},{"key":"68156_CR37","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41388-025-03342-y","volume":"44","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer. Oncogene 44, 1731\u20131745 (2025).","journal-title":"Oncogene"},{"key":"68156_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi, H., Hsu, J. M., Yang, W. H. & Hung, M. C. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat. Rev. Clin. Oncol. 19, 287\u2013305 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68156_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359\u2013370 (2019).","journal-title":"Mol. Cell"},{"key":"68156_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).","journal-title":"Nat. Commun."},{"key":"68156_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23864-9","volume":"12","author":"M Wu","year":"2021","unstructured":"Wu, M., Xia, X., Hu, J., Fowlkes, N. W. & Li, S. WSX1 acts as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat. Commun. 12, 3500 (2021).","journal-title":"Nat. Commun."},{"key":"68156_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45712-2","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling the cytoskeleton to STAT1 activation and PD-L1 expression. Nat. Commun. 15, 1314 (2024).","journal-title":"Nat. Commun."},{"key":"68156_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91\u201395 (2018).","journal-title":"Nature"},{"key":"68156_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"A Kornepati","year":"2022","unstructured":"Kornepati, A., Vadlamudi, R. K. & Curiel, T. J. Programmed death ligand 1 signals in cancer cells. Nat. Rev. Cancer 22, 174\u2013189 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"68156_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","volume":"26","author":"X Yang","year":"2014","unstructured":"Yang, X. et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26, 577\u2013590 (2014).","journal-title":"Cancer Cell"},{"key":"68156_CR46","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jtho.2016.05.010","volume":"11","author":"YW Wang","year":"2016","unstructured":"Wang, Y. W. et al. ITPKA gene body methylation regulates gene expression and serves as an early diagnostic marker in lung and other cancers. J. Thorac. Oncol. 11, 1469\u20131481 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"68156_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05550-5","volume":"9","author":"M Arechederra","year":"2018","unstructured":"Arechederra, M. et al. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat. Commun. 9, 3164 (2018).","journal-title":"Nat. Commun."},{"key":"68156_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ebiom.2019.08.064","volume":"47","author":"G Li","year":"2019","unstructured":"Li, G. et al. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine 47, 128\u2013141 (2019).","journal-title":"EBioMedicine"},{"key":"68156_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature14176","volume":"520","author":"T Baubec","year":"2015","unstructured":"Baubec, T. et al. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature 520, 243\u2013247 (2015).","journal-title":"Nature"},{"key":"68156_CR50","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1038\/sj.onc.1203784","volume":"19","author":"AM Johnston","year":"2000","unstructured":"Johnston, A. M. et al. SPAK, a STE20\/SPS1-related kinase that activates the p38 pathway. Oncogene 19, 4290\u20134297 (2000).","journal-title":"Oncogene"},{"key":"68156_CR51","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1152\/physrev.00009.2012","volume":"92","author":"KB Gagnon","year":"2012","unstructured":"Gagnon, K. B. & Delpire, E. Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport. Physiol. Rev. 92, 1577\u20131617 (2012).","journal-title":"Physiol. Rev."},{"key":"68156_CR52","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.7150\/thno.62406","volume":"11","author":"Z Qiu","year":"2021","unstructured":"Qiu, Z. et al. STK39 promotes breast cancer invasion and metastasis by increasing SNAI1 activity upon phosphorylation. Theranostics 11, 7658\u20137670 (2021).","journal-title":"Theranostics"},{"key":"68156_CR53","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.7150\/thno.48112","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1\/ERK signaling pathway. Theranostics 11, 2108\u20132122 (2021).","journal-title":"Theranostics"},{"key":"68156_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103223","volume":"24","author":"X Hao","year":"2021","unstructured":"Hao, X. et al. STK39 enhances the progression of Cholangiocarcinoma via PI3K\/AKT pathway. iScience 24, 103223 (2021).","journal-title":"iScience"},{"key":"68156_CR55","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1080\/21655979.2021.1973876","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Knockdown of STK39 suppressed cell proliferation, migration, and invasion in hepatocellular carcinoma by repressing the phosphorylation of mitogen-activated protein kinase p38. Bioengineered 12, 6529\u20136537 (2021).","journal-title":"Bioengineered"},{"key":"68156_CR56","doi-asserted-by":"publisher","first-page":"13881","DOI":"10.1093\/nar\/gkae1099","volume":"52","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. STK39-mediated amplification of \u03b3-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance. Nucleic Acids Res. 52, 13881\u201313895 (2024).","journal-title":"Nucleic Acids Res."},{"key":"68156_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0092-8674(03)00042-4","volume":"112","author":"R Eferl","year":"2003","unstructured":"Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181\u2013192 (2003).","journal-title":"Cell"},{"key":"68156_CR58","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ncb2590","volume":"14","author":"L Min","year":"2012","unstructured":"Min, L. et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 14, 1203\u20131211 (2012).","journal-title":"Nat. Cell Biol."},{"key":"68156_CR59","first-page":"51","volume":"10","author":"F Villarruel-Melquiades","year":"2024","unstructured":"Villarruel-Melquiades, F. et al. Activator protein-1 in liver pathology: from precancerous diseases to hepatocellular carcinoma. Hepatoma Res. 10, 51 (2024).","journal-title":"Hepatoma Res."},{"key":"68156_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.20517\/2394-5079.2022.37","volume":"9","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Wakil, A., Salomon, F. & Pyrsopoulos, N. Issue on combined locoregional and systemic treatment for hepatocellular carcinoma. Hepatoma Res. 9, 6 (2023).","journal-title":"Hepatoma Res."},{"key":"68156_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02199-1","volume":"23","author":"Y Lao","year":"2024","unstructured":"Lao, Y. et al. Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma. Mol. Cancer 23, 283 (2024).","journal-title":"Mol. Cancer"},{"key":"68156_CR62","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","volume":"187","author":"SR Savage","year":"2024","unstructured":"Savage, S. R. et al. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell 187, 4389\u20134407.e15 (2024).","journal-title":"Cell"},{"key":"68156_CR63","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama, A. & Nakanishi, M. Navigating the DNA methylation landscape of cancer. Trends Genet. 37, 1012\u20131027 (2021).","journal-title":"Trends Genet."},{"key":"68156_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01382-9","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin. Epigenetics 14, 154 (2022).","journal-title":"Clin. Epigenetics"},{"key":"68156_CR65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-019-1534-3","volume":"573","author":"DN Weinberg","year":"2019","unstructured":"Weinberg, D. N. et al. The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature 573, 281\u2013286 (2019).","journal-title":"Nature"},{"key":"68156_CR66","first-page":"01422","volume":"S0092-8674","author":"G Quarto","year":"2025","unstructured":"Quarto, G. et al. Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation. Cell S0092-8674, 01422\u201301423 (2025).","journal-title":"Cell"},{"key":"68156_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature09165","volume":"466","author":"AK Maunakea","year":"2010","unstructured":"Maunakea, A. K. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253\u2013257 (2010).","journal-title":"Nature"},{"key":"68156_CR68","doi-asserted-by":"publisher","first-page":"e14379","DOI":"10.14814\/phy2.14379","volume":"8","author":"CJ Mercado","year":"2020","unstructured":"Mercado, C. J., Wang, X., Grimm, P. R., Welling, P. A. & Chang, Y. C. Identification and characterization of alternative STK39 transcripts within human and mouse kidneys reveals species-specific regulation of blood pressure. Physiol. Rep. 8, e14379 (2020).","journal-title":"Physiol. Rep."},{"key":"68156_CR69","doi-asserted-by":"crossref","unstructured":"Sie, Z. L. et al. WNK1 Kinase Stimulates Angiogenesis to Promote Tumor Growth and Metastasis. Cancers 12, 575 (2020).","DOI":"10.3390\/cancers12030575"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68156-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T01:03:20Z","timestamp":1770426200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68156"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68156-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1414"}}